Reviewing Theravance Biopharma (TBPH) and Its Competitors
Theravance Biopharma (NASDAQ: TBPH) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Theravance Biopharma to related companies based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, risk, dividends and profitability.
Valuation & Earnings
This table compares Theravance Biopharma and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Theravance Biopharma||$31.36 million||-$211.25 million||-6.23|
|Theravance Biopharma Competitors||$8.08 billion||$2.63 billion||-0.02|
Theravance Biopharma’s peers have higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Theravance Biopharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Theravance Biopharma Competitors||-2,858.55%||-1,953.34%||-9.53%|
Volatility & Risk
Theravance Biopharma has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Theravance Biopharma’s peers have a beta of 0.95, suggesting that their average stock price is 5% less volatile than the S&P 500.
Insider & Institutional Ownership
84.9% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.1% of Theravance Biopharma shares are owned by insiders. Comparatively, 11.9% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of recent recommendations for Theravance Biopharma and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Theravance Biopharma Competitors||847||3784||6815||185||2.54|
Theravance Biopharma presently has a consensus price target of $42.67, indicating a potential upside of 47.84%. As a group, “Pharmaceuticals” companies have a potential upside of 23.10%. Given Theravance Biopharma’s stronger consensus rating and higher probable upside, equities analysts plainly believe Theravance Biopharma is more favorable than its peers.
Theravance Biopharma beats its peers on 7 of the 12 factors compared.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.